KISUNLA

This brand name is authorized in United States

Active ingredients

The drug KISUNLA contains one active pharmaceutical ingredient (API):

1 Donanemab
UNII 1ADB65P1KK - DONANEMAB

Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. Donanemab-azbt reduces amyloid beta plaques, as evaluated in Study 1.

Read about Donanemab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
KISUNLA Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N06DX05 N Nervous system → N06 Psychoanaleptics → N06D Anti-dementia drugs → N06DX Other anti-dementia drugs
Discover more medicines within N06DX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: US FDA, National Drug Code Identifier(s): 0002-9401

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.